Skip to main content

Lluis Armadans Gil

Institutions of which they are part

Senior researcher
Epidemiology and Public Health
Vall Hebron Institut de Recerca

Lluis Armadans Gil

Institutions of which they are part

Senior researcher
Epidemiology and Public Health
Vall Hebron Institut de Recerca

Projects

Valoración del envejecimiento de la población hospitalizada.

IP: Antonio San Jose Laporte
Collaborators: Lluis Armadans Gil
Funding agency: Instituto de Salud Carlos III
Funding: 13800
Reference: PI020516
Duration: 06/11/2002 - 06/11/2004

Análisis coste-efectividad de los productos sanitarios con mecanismos de seguridad para prevenir las exposiciones percutáneas con alto riesgo de transmisión de microorganismos séricos

IP: Lluis Armadans Gil
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 1983.34
Reference: 01/1391
Duration: 17/07/2001 - 31/08/2003

Estudio de la angiogénesis y la respuesta inflamatoria en la patogenia de las complicaciones de los derrames pleurales bacterianos.

IP: José Alegre Martin
Collaborators: Tomás Fernández de Sevilla Ribosa, Lluis Armadans Gil, Jordi Andreu Soriano, Teresa Soriano Sánchez, Maria Carmen Aleman Llanso, Eva Ruiz Ruiz
Funding agency: Instituto de Salud Carlos III
Funding: 23138.97
Reference: 01/1408
Duration: 17/07/2001 - 31/12/2002

Estudio de la asociación entre el equilibrio de las metaloproteinasas y sus inhibidores tisulares, con el sistema de la fibrinolisis pleural y los marcadores de activación neutrofílica en los derrames pleurales bacterianos.

IP: José Alegre Martin
Collaborators: Lluis Armadans Gil, Maria Carmen Aleman Llanso
Funding agency: Instituto de Salud Carlos III
Funding: 22117.25
Reference: 99/0812
Duration: 01/11/1999 - 01/11/2000

Related news

The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban.

On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.

This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.

Related professionals

Alberto Roque Pérez

Alberto Roque Pérez

Molecular Imaging and Therapy
Read more
Esperanza Esteban Serna

Esperanza Esteban Serna

Main researcher
Infectious Diseases
Read more
Emma Pardo De los Santos

Emma Pardo De los Santos

Research technician
Nephrology and kidney transplantation
Read more
Fátima Jiménez Mamolar

Fátima Jiménez Mamolar

P. Management and Admin. Technical specialist
Manager
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.